Document is current
Any future updates will be listed below
-
Authors
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02694523 at ClinicalTrials.govnct03047395 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
https://doi.org/10.1007/s13555-024-01229-6
Exposure–Response Relationships for the Efficacy and Safety of Risankizumab in Japanese Subjects with Psoriasis
https://doi.org/10.1007/s40262-019-00829-2
nct02207224 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
https://doi.org/10.1007/s13555-024-01229-6
Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results
https://doi.org/10.1007/s40257-025-00964-6
nct02576431 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
https://doi.org/10.1007/s13555-024-01229-6
nct03482011 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
https://doi.org/10.1007/s13555-024-01229-6
Larotrectinib (laro) long-term efficacy and safety in patients (pts) with tropomyosin receptor kinase (TRK) fusion thyroid carcinoma (TC).
https://doi.org/10.1200/jco.2023.41.16_suppl.6091
Precision oncology: separating the wheat from the chaff
https://doi.org/10.1136/esmoopen-2018-000446
Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
https://doi.org/10.1200/jco.2023.41.16_suppl.9056
Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.
https://doi.org/10.1200/jco.2023.41.16_suppl.3141
Long-term efficacy and safety of larotrectinib in patients with TRK fusion lung cancer.
https://doi.org/10.1200/jco.2024.42.16_suppl.8570
Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.
https://doi.org/10.1200/jco.2024.42.3_suppl.109
Long-term efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion thyroid carcinoma (TC).
https://doi.org/10.1200/jco.2024.42.16_suppl.6095
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors
https://doi.org/10.1200/jco.24.00848
nct03556202 at ClinicalTrials.govDocuments that mention this clinical trial
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
https://doi.org/10.1007/s13555-024-01229-6
Documents that mention this clinical trial
Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis
https://doi.org/10.1007/s13555-024-01229-6
- License Information
-
More Information
Article History
Received: 22 April 2024
Accepted: 2 July 2024
First Online: 29 July 2024
Declarations
:
: Chang-Yu Hsieh received honoraria for educational events from Boehringer Ingelheim. Francis Li-Tien Hsu has no conflict of interest. Tsen-Fang Tsai has conducted clinical trials or received honoraria for serving as a consultant for Abbvie, AnaptysBio, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli-Lilly, Galderma, GSK, Janssen-Cilag, Leo Pharma, Merck Sharp & Dohme, Novartis International, Pfizer, PharmaEssentia, Sanofi, Sun Pharma, and UCB Pharma. Tsen-Fang Tsai is an Editorial Board member of Dermatology and Therapy. Tsen-Fang Tsai was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.
: This study was conducted with the approval of institutional review board from National Taiwan University Hospital (201904124RINC). All included patients provided written consent for data collection. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.
